CGEMCullinan Oncology, Inc.

Nasdaq cullinanoncology.com


$ 25.30 $ 6.05 (31.43 %)    

Friday, 26-Apr-2024 15:59:58 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 25.3
$ 19.45
$ 0.00 x 0
$ 25.30 x 200
$ 19.45 - $ 25.65
$ 7.64 - $ 25.72
4,747,718
na
1.05B
$ 0.69
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-09-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-17-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-is-cullinan-therapeutics-stock-trading-higher-on-wednesday

Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN...

 cullinan-therapeutics-to-present-clinical-data-from-phase-1-study-evaluating-novel-anti-micab-antibody-cln-619-as-monotherapy-and-in-combination-with-a-checkpoint-inhibitor-in-patients-with-advanced-solid-tumors-at-asco-2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today a...

 why-travelers-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

 btig-maintains-buy-on-cullinan-oncology-raises-price-target-to-30

BTIG analyst Kaveri Pohlman maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and raises the price target from $20 to $30.

 united-airlines-reports-upbeat-results-joins-childrens-place-interactive-brokers-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday.

 hc-wainwright--co-maintains-buy-on-cullinan-oncology-lowers-price-target-to-29

HC Wainwright & Co. analyst Edward White maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and lowers the price targe...

 why-skillsoft-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter...

 cullinan-shifts-focus-from-oncology-to-autoimmune-disorders-raises-280m-via-equity

Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show p...

 hc-wainwright--co-maintains-buy-on-cullinan-oncology-lowers-price-target-to-29

HC Wainwright & Co. analyst Edward White maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and lowers the price targe...

 unitedhealth-reports-upbeat-earnings-joins-cullinan-oncology-ericsson-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday.

Core News & Articles
Market-Moving news for April 16th
04/16/2024 12:36:44

CGEM: 23% | Cullinan Therapeutics To Pursue Development Of CLN-978 In Autoimmune Diseases, With Systemic Lupus Erythematosus As...

 cullinan-therapeutics-to-pursue-development-of-cln-978-in-autoimmune-diseases-with-systemic-lupus-erythematosus-as-first-indication-discontinued-enrollment-in-its-b-nhl-study-to-focus-ongoing-development-on-autoimmune-indications

CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indi...

 william-blair-initiates-coverage-on-cullinan-oncology-with-outperform-rating

William Blair analyst Matt Phipps initiates coverage on Cullinan Oncology (NASDAQ:CGEM) with a Outperform rating.

 hc-wainwright--co-reiterates-buy-on-cullinan-oncology-maintains-34-price-target

HC Wainwright & Co. analyst Edward White reiterates Cullinan Oncology (NASDAQ:CGEM) with a Buy and maintains $34 price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION